Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00137813 · ClinicalTrials.gov registry record · Phase 2
Avastin and Taxotere for Esophagogastric Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT00137813 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 42 participants.
The verdict
NCT00137813, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this study is to determine what effects (good and bad) bevacizumab (Avastin) and docetaxel (Taxotere), used in combination, have on metastatic gastric and esophageal cancer.
Interventions
- DRUG Bevacizumab
- DRUG Docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2004-08 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00137813
The ClinicalTrials.gov registry entry for NCT00137813 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT00137813 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00137813 about?
NCT00137813 is a clinical study titled "Avastin and Taxotere for Esophagogastric Cancer". The purpose of this study is to determine what effects (good and bad) bevacizumab (Avastin) and docetaxel (Taxotere), used in combination, have on metastatic gastric and esophageal cancer.
What is the current status of trial NCT00137813?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2004-08. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00137813?
The interventions under investigation include: Bevacizumab (DRUG), Docetaxel (DRUG).
Who is sponsoring clinical trial NCT00137813?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.